In vivo evaluation of [18F]fluoroetanidazole as a new marker for imaging tumour hypoxia with positron emission tomography

Barthel, Henryk; Wilson, H. F.; Collingridge, David R.; Brown, Gavin; Osman, Safiye; Luthra, Sajinder K.; Brady, F.; Workman, Paul; Price, Pat; Aboagye, Eric O.

doi:10.1038/sj.bjc.6601862

Cited by 92 publications

(45 citation statements)

References 61 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…A careful biologic evaluation of 18 F-FETA found that this second-generation agent had potential advantageous physicochemical properties. Most notably it was stable to nonhypoxic degradation in vivo (102)…”

Section: Fluoromisonidazole and Related Nitroimidazoles: Clinical Stumentioning

confidence: 99%

Molecular Imaging of Hypoxia

2008

View full text Add to dashboard Cite

Section: Fluoromisonidazole and Related Nitroimidazoles: Clinical Stumentioning

confidence: 99%

Molecular Imaging of Hypoxia

2008

View full text Add to dashboard Cite

“…Reischl et al [165] , Piert et al [166] , Picchio et al [167] , Maier et al [168] , Tran et al [169] Barthel et al [187] Busk et al [170] , Mortensen et al [171] , Piert et al [166] , Tran et al [169] Barthel et al [187] Busk et al [170] , Busk et al [172] , Busk et al [173] , Busk et al [174] , Busk et al [175] , Graves et al [176] , Maier et al [168] , Solomon et al [177] NA Belloli et al [178] , Picchio et al [167] , Troost et al [179] , Valtorta et al [143] NA Sorger et al [57] , Piert et al [166] , Reischl et al [165] Rasey et al [188] Postema et al [180] , Bollineni et al [181] , Trinkaus et al [58] , Verwer et al [59] NA Grosu et al [182] , Souvatzoglou et al [183] , Schuetz et al [184] , Shi et al [106] , Mortensen et al [185] , Havelund et al [186] NA…”

Section: F]ef5mentioning

confidence: 99%

Positron emission tomography to assess hypoxia and perfusion in lung cancer

Verwer

Boellaard

Veldt

2014

WJCO

View full text Add to dashboard Cite

Core tip:This review provides an overview of the current applications of positron emission tomography for hypoxia and perfusion imaging in lung cancer. Available PET tracers are discussed and the benefits of combined hypoxia and perfusion PET imaging are clarified. Hypoxia imaging could aid in selecting patients for hypoxia-specific treatment strategies. To achieve this, consensus about the optimal imaging protocol and quantification method is essential. Large clinical trials are needed to confirm the value of hypoxia imaging for improving patient care.Verwer EE, Boellaard R, van der Veldt AAM. Positron emission tomography to assess hypoxia and perfusion in lung cancer.

show abstract

“…[32][33][34] We therefore require both a means of determining the intrinsic values of α, β and γ, and techniques for quantitatively imaging the distribution of clonogenic cell density and of hypoxia. Recent advances in positron emission tomography (PET) and magnetic resonance imaging and spectroscopy, particularly the development of new techniques for imaging tumor cell metabolism 35,36 and hypoxia, [37][38][39][40] show progress towards fulfilling the imaging requirements. Here we present methods for quantifying the intrinsic radiobiological parameters for a specific patient.…”

Section: Iib Radiobiological Modelmentioning

confidence: 99%

A theoretical framework for prescribing radiotherapy dose distributions using patient‐specific biological information

2008

View full text Add to dashboard Cite

We present a formalism for using functional imaging both to derive patient-specific radiobiological properties and consequently to prescribe optimal non-uniform radiotherapy dose distributions. The ability to quantitatively assess the response to an initial course of radiotherapy would allow the derivation of radiobiological parameters for individual patients.Both an iterative optimization and an analytical approach to this problem were investigated and illustrated by application to the linear-quadratic model of cell killing using simulated parametric data for a modelled tumor. Potential gains in local control were assessed by comparing uniform dose distributions with optimized dose distributions of equal integral dose. The effect on local prescribed dose of variations in effective radiosensitivity, tumor burden and proliferation rate was investigated, with results suggesting that dose variations would be significant but clinically achievable. The sensitivity of derived parameters to image noise and the effect of varying the initial fractionation and imaging schedule were assessed.The analytical approach proved remarkably robust, with 10% image noise resulting in dose errors of approximately 1% for a clinically relevant set of parameters. Potential benefits were demonstrated by using this formalism to prescribe non-uniform dose distributions for model tumors using a range of literature-derived parameters. The redistribution of dose improved tumor control probability by factors between 1.03 and 4.27 for a range of model tumors.Prescribing radiotherapy dose distributions using patient-specific information 2

show abstract

In vivo evaluation of [18F]fluoroetanidazole as a new marker for imaging tumour hypoxia with positron emission tomography

Abstract: Development of hypoxia-targeted therapies has stimulated the search for clinically applicable noninvasive markers of tumour hypoxia. Here, we describe the validation of

Cited by 92 publications

References 61 publications

Molecular Imaging of Hypoxia

Molecular Imaging of Hypoxia

Positron emission tomography to assess hypoxia and perfusion in lung cancer

A theoretical framework for prescribing radiotherapy dose distributions using patient‐specific biological information

Contact Info

Product

Resources

About